...

首页> 外文期刊>Journal of Clinical Oncology >Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial

【24h】

Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial

机译：多西紫杉醇单药治疗或与雷莫昔单抗或依库美单抗联合用于局部晚期或转移性尿路上皮癌的二线治疗：开放标签，三臂，随机对照II期试验

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

Purpose

机译：目的

著录项

来源
《Journal of Clinical Oncology》 |2016年第13期|共18页
作者
Petrylak Daniel P.; Tagawa Scott T.; Kohli Manish; Eisen Andrea; Canil Christina; Sridhar Srikala S.; Spira Alexander; Yu Evan Y.; Burke John M.; Shaffer David; Pan Chong-Xian; Kim Jenny J.; Aragon-Ching Jeanny B.; Quinn David I.; Vogelzang Nicholas J.; Tang Shande; Zhang Hui; Cavanaugh Christopher T.; Gao Ling; Kauh John S.; Walgren Richard A.; Chi Kim N.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial [J] . Petrylak Daniel P., Tagawa Scott T., Kohli Manish, Journal of Clinical Oncology . 2016,第13期

机译：多西紫杉醇单药治疗或与雷莫昔单抗或依库美单抗联合用于局部晚期或转移性尿路上皮癌的二线治疗：开放标签，三臂，随机对照II期试验
2. Re: Ramucirumab plus Docetaxel versus Placebo plus Docetaxel in Patients with Locally Advanced or Metastatic Urothelial Carcinoma after Platinum-Based Therapy (RANGE): A Randomised, Double-Blind, Phase 3 Trial [J] . Chang Sam S. The Journal of Urology . 2019,第6期

机译：Re：Ramucirumab Plus Docetaxel与安慰剂加入多西紫杉醇在基于铂类的治疗（范围）后局部晚期或转移性尿路上皮癌的患者：随机，双盲，第3阶段试验
3. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial (vol 391, pg 748, 2018) [J] . Powles T., Duran I, van der Heijden M. The Lancet . 2018,第10156期

机译：紫红素与化疗在铂治疗的局部晚期或转移性尿路上皮癌（IMVigor211）中：多期，开放标签，第3阶段随机对照试验（Vol 391，PG 748,2018）
4. Designing Phase III Trials in Metastatic Renal Cell Carcinoma: What Are the New Standards? [C] . Ana M. Molina Genitourinary Cancers Symposium . 2012

机译：在转移性肾细胞癌中设计III期试验：新标准是什么？
5. Phase II double-blinded randomized controlled clinical trial of chondroitinase ABC by intraspinal injection for treatment of severe chronic spinal cord injury in 60 pet dogs. [D] . Hu, Hilary. 2016

机译：脊髓内注射软骨素酶ABC的II期双盲随机对照临床试验，用于治疗60只宠物狗的严重慢性脊髓损伤。
6. Trastuzumab pertuzumab and eribulin mesylate versus trastuzumab pertuzumab and a taxane as a first-line or second-line treatment for HER2-positive locally advanced or metastatic breast cancer: study protocol for a randomized controlled non-inferiority phase III trial in Japan (JBCRG-M06/EMERALD) [O] . Toshinari Yamashita, Norikazu Masuda, Shigehira Saji, 2020

机译：曲妥珠单抗帕妥珠单抗和甲磺酸艾瑞布林与曲妥珠单抗帕妥珠单抗和紫杉烷作为一线或二线治疗HER2阳性局部晚期或转移性乳腺癌的一线或二线治疗：III期随机对照非劣效性的研究方案在日本试用（JBCRG-M06 / EMERALD）
7. Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD) [O] . Toshinari Yamashita, Norikazu Masuda, Shigehira Saji, 2020

机译：校正至：Trastuzumab，Pertuzumab和Eribulin甲蛋白与曲妥珠单抗，Pertuzumab和紫杉烷作为Her2阳性，局部晚期或转移性乳腺癌的一线或二线治疗：用于随机控制，非劣势的研究方案，日本第三阶段试验（JBCRG-M06 / Emerald）

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号